Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease

Diabetes and Metabolism

Volumn 44, Issue 6, 2018, Pages 457-464

  Bonnet, F ^a,b   Scheen, A J ^c,d  

^a UNIVERSITÉ DE RENNES 1   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular disease; Chronic kidney disease; Diabetic complications; Inflammation; SGLT2 inhibitors; Type 2 diabetes

Indexed keywords

3 HYDROXYBUTYRIC ACID; FAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; URIC ACID;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CLINICAL STUDY; DIABETIC COMPLICATION; DRUG EFFICACY; ENZYME ACTIVATION; HEART; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; KIDNEY; LIVER; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET; REVIEW; URIC ACID BLOOD LEVEL; VASCULAR ENDOTHELIAL CELL; ANIMAL; COMPLICATION; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85054466162     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2018.09.005     Document Type: Review

References (125)

1. Prattichizzo, F, De Nigris, V, Spiga, R, Mancuso, E, La Sala, L, Antonicelli, R, et al. Inflammageing and metaflammation: the yin and yang of type 2 diabetes. Ageing Res Rev 41 (2018), 1–17.
2. Libby, P, Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32 (2012), 2045–2051.
3. Karasawa, T, Takahashi, M, Role of NLRP3 inflammasomes in atherosclerosis. J Atheroscler Thromb 24 (2017), 443–451.
4. Scheen, AJ, Esser, N, Paquot, N, Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. Diabetes Metab 41 (2015), 183–194.
5. Pereira, CA, Carneiro, FS, Matsumoto, T, Tostes, RC, Bonus effects of antidiabetic drugs: possible beneficial effects on endothelial dysfunction, vascular inflammation and atherosclerosis. Basic Clin Pharmacol Toxicol, 2018, 10.1111/bcpt.13054 [Epub ahead of print].
6. Zinman, B, Wanner, C, Lachin, JM, Fitchett, D, Bluhmki, E, Hantel, S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
7. Neal, B, Perkovic, V, Mahaffey, KW, de Zeeuw, D, Fulcher, G, Erondu, N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
8. Wanner, C, Inzucchi, SE, Lachin, JM, Fitchett, D, von Eynatten, M, Mattheus, M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
9. Perkovic, V, Zeeuw, D, Mahaffey, KW, Fulcher, G, Erondu, N, Shaw, W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 6 (2018), 691–704.
10. Scheen, AJ, Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis. Diabetes Metab 42 (2016), 71–76.
11. Staels, B, Cardiovascular protection by sodium-glucose cotransporter 2 inhibitors: potential mechanisms. Am J Cardiol 120 (2017), S28–S36.
12. Vallon, V, Thomson, SC, Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60 (2017), 215–225.
13. Sharma, A, Tate, M, Mathew, G, Vince, JE, Ritchie, RH, de Haan, JB, Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Front Physiol, 9, 2018, 114.
14. Ridker, PM, Everett, BM, Thuren, T, MacFadyen, JG, Chang, WH, Ballantyne, C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
15. Ridker, PM, MacFadyen, JG, Everett, BM, Libby, P, Thuren, T, Glynn, RJ, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391 (2018), 319–328.
16. Donath, MY, Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 13 (2014), 465–476.
17. Pollack, RM, Donath, MY, LeRoith, D, Leibowitz, G, Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 39:2 (2016), S244–S252.
18. Bailey, CJ, Iqbal, N, T'Joen, C, List, JF, Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14 (2012), 951–959.
19. Matsumura, M, Nakatani, Y, Tanka, S, Aoki, C, Sagara, M, Yanagi, K, et al. Efficacy of additional canagliflozin administration to type 2 diabetes patients receiving insulin therapy: examination of diurnal glycemic patterns using continuous glucose monitoring (CGM). Diabetes Ther 8 (2017), 821–827.
20. Garvey, TW, Van Gaal, L, Leiter, LA, Vijapurkar, U, List, J, Cuddihy, R, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism 85 (2018), 32–37.
21. Ferrannini, E, Ramos, SJ, Salsali, A, Tang, W, List, JF, Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33 (2010), 2217–2224.
22. Okamoto, A, Yokokawa, H, Sanada, H, Naito, T, Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. Drugs R D 16 (2016), 255–261.
23. Hattori, S., Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance. J Diabetes Investig 9 (2018), 870–874.
24. Tobita, H, Sato, S, Miyake, T, Ishihara, S, Kinoshita, Y, Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp 87 (2017), 13–19.
25. Sato, T, Aizawa, Y, Yuasa, S, Kishi, S, Fuse, K, Fujita, S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol, 17, 2018, 6.
26. Tan, SA, Tan, L, Empagliflozin and canagliflozin attenuate inflammatory cytokines interferon-λ tumor necrosis facror-α interleukin-6: possible mechnaism of decreasing cardiovascular risk in diabetes mellitus (abstract). JACC Heart failure 17 (2018), 1212–1411, 10.016/S0735-1097(18)32371-4 [Poster].
27. Van Gaal, LF, Mertens, IL, De Block, CE, Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006), 875–880.
28. Sam, S, Haffner, S, Davidson, MH, D'Agostino, RB Sr., Feinstein, S, Kondos, G, et al. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 32 (2009), 932–937.
29. Asghar, A, Sheikh, N, Role of immune cells in obesity induced low-grade inflammation and insulin resistance. Cell Immunol 315 (2017), 18–26.
30. Xu, L, Ota, T, Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization. Adipocyte, 2017, 10.1080/21623945.2017.1413516 [Epub ahead of print].
31. Xu, L, Nagata, N, Nagashimada, M, Zhuge, F, Ni, Y, Chen, G, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine 20 (2017), 137–149.
32. Esser, N, L'Homme, L, De Roover, A, Kohnen, L, Scheen, AJ, Moutschen, M, et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 56 (2013), 2487–2497.
33. Packer, M, Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab 20 (2018), 1361–1366.
34. Abazid, RM, Smettei, OA, Kattea, MO, Sayed, S, Saqqah, H, Widyan, AM, et al. Relation between epicardial fat and subclinical atherosclerosis in asymptomatic individuals. J Thorac Imaging 32 (2017), 378–382.
35. Fukuda, T, Bouchi, R, Terashima, M, Sasahara, Y, Asakawa, M, Takeuchi, T, et al. Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther 8 (2017), 851–861.
36. Bouchi, R, Terashima, M, Sasahara, Y, Asakawa, M, Fukuda, T, Takeuchi, T, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol, 16, 2017, 32.
37. Sato, Y, Kamada, T, Yamauchi, A, The role of dipeptidyl peptidase 4 (DPP4) in the preservation of renal function: DPP4 involvement in hemoglobin expression. J Endocrinol 223 (2014), 133–142.
38. Diaz-Rodriguez, E, Agra, RM, Fernandez, AL, Adrio, B, Garcia-Caballero, T, Gonzalez-Juanatey, JR, et al. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res 114 (2018), 336–346.
39. Bullo, M, Garcia-Lorda, P, Megias, I, Salas-Salvado, J, Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 11 (2003), 525–531.
40. Shoelson, SE, Herrero, L, Naaz, A, Obesity, inflammation, and insulin resistance. Gastroenterology 132 (2007), 2169–2180.
41. Byrne, CD, Targher, G, NAFLD: a multisystem disease. J Hepatol 62 (2015), S47–64.
42. Genc, H, Dogru, T, Kara, M, Tapan, S, Ercin, CN, Acikel, C, et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol 12 (2013), 548–555.
43. Bi, Y, Min, M, Shen, W, Deng, P, Du, Q, Dong, M, et al. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease. Int J Clin Exp Pathol 8 (2015), 8494–8499.
44. Chiang, CH, Huang, CC, Chan, WL, Chen, JW, Leu, HB, The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clin Biochem 43 (2010), 1399–1404.
45. Al Rifai, M, Silverman, MG, Nasir, K, Budoff, MJ, Blankstein, R, Szklo, M, et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 239 (2015), 629–633.
46. Simon, TG, Trejo, MEP, McClelland, R, Bradley, R, Blaha, MJ, Zeb, I, et al. Circulating interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol 259 (2018), 198–204.
47. Sumida, Y, Yoneda, M, Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 53 (2018), 362–376.
48. Seko, Y, Sumida, Y, Tanaka, S, Mori, K, Taketani, H, Ishiba, H, et al. Effect of sodium-glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res 47 (2017), 1072–1078.
49. Kuchay, MS, Krishan, S, Mishra, SK, Farooqui, KJ, Singh, MK, Wasir, JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 41 (2018), 1801–1808.
50. Li, B, Wang, Y, Ye, Z, Yang, H, Cui, X, Wang, Z, et al. Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. J Pharm Pharm Sci 21 (2018), 222–235.
51. Eriksson, JW, Lundkvist, P, Jansson, PA, Johansson, L, Kvarnstrom, M, Moris, L, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 61 (2018), 1923–1934.
52. Kurinami, N, Sugiyama, S, Yoshida, A, Hieshima, K, Miyamoto, F, Kajiwara, K, et al. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract 142 (2018), 254–263.
53. Ito, D, Shimizu, S, Inoue, K, Saito, D, Yanagisawa, M, Inukai, K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care 40 (2017), 1364–1372.
54. Takeda, A, Irahara, A, Nakano, A, Takata, E, Koketsu, Y, Kimata, K, et al. The Improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium-glucose cotransporter 2 inhibitor ipragliflozin. Intern Med 56 (2017), 2739–2744.
55. Shibuya, T, Fushimi, N, Kawai, M, Yoshida, Y, Hachiya, H, Ito, S, et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab 20 (2018), 438–442.
56. Leiter, LA, Forst, T, Polidori, D, Balis, DA, Xie, J, Sha, S, Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 42 (2016), 25–32.
57. Komiya, C, Tsuchiya, K, Shiba, K, Miyachi, Y, Furuke, S, Shimazu, N, et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One, 11, 2016, e0151511.
58. Tesch, GH, Diabetic nephropathy – is this an immune disorder?. Clin Sci (Lond) 131 (2017), 2183–2199.
59. Festa, A, D'Agostino, R, Howard, G, Mykkanen, L, Tracy, RP, Haffner, SM, Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int 58 (2000), 1703–1710.
60. Stehouwer, CD, Gall, MA, Twisk, JW, Knudsen, E, Emeis, JJ, Parving, HH, Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51 (2002), 1157–1165.
61. Moriwaki, Y, Yamamoto, T, Shibutani, Y, Aoki, E, Tsutsumi, Z, Takahashi, S, et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52 (2003), 605–608.
62. Ojima, A, Matsui, T, Nishino, Y, Nakamura, N, Yamagishi, S, Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res 47 (2015), 686–692.
63. Ishibashi, Y, Matsui, T, Yamagishi, S, Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res 48 (2016), 191–195.
64. Jaikumkao, K, Pongchaidecha, A, Chueakula, N, Thongnak, LO, Wanchai, K, Chatsudthipong, V, et al. Dapagliflozin, a SGLT2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, ER stress, and apoptosis in pre-diabetic rats. Diabetes Obes Metab, 2018, 10.1111/dom.13441 [Epub ahead of print].
65. Ishibashi, Y, Matsui, T, Yamagishi, SI, Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals. Diab Vasc Dis Res 13 (2016), 438–441.
66. Kawanami, D, Matoba, K, Takeda, Y, Nagai, Y, Akamine, T, Yokota, T, et al. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci, 18, 2017.
67. Terami, N, Ogawa, D, Tachibana, H, Hatanaka, T, Wada, J, Nakatsuka, A, et al. Long-term treatment with the sodium-glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One, 9, 2014, e100777.
68. Wang, XX, Levi, J, Luo, Y, Myakala, K, Herman-Edelstein, M, Qiu, L, et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem 292 (2017), 5335–5348.
69. Dekkers, CCJ, Petrykiv, S, Laverman, GD, Cherney, DZ, Gansevoort, RT, Heerspink, HJL, Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 20 (2018), 1988–1993.
70. Jardine, MJ, Mahaffey, KW, Neal, B, Agarwal, R, Bakris, GL, Brenner, BM, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46 (2017), 462–472.
71. Ye, Y, Bajaj, M, Yang, HC, Perez-Polo, JR, Birnbaum, Y, SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther 31 (2017), 119–132.
72. Lee, TM, Chang, NC, Lin, SZ, Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 104 (2017), 298–310.
73. Nakatsu, Y, Kokubo, H, Bumdelger, B, Yoshizumi, M, Yamamotoya, T, Matsunaga, Y, et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice. Int J Mol Sci, 18(8), 2017, E1704, 10.3390/ijms18081704.
74. Han, JH, Oh, TJ, Lee, G, Maeng, HJ, Lee, DH, Kim, KM, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-/-) mice fed a western diet. Diabetologia 60 (2017), 364–376.
75. Tahara, A, Takasu, T, Yokono, M, Imamura, M, Kurosaki, E, Characterization and comparison of SGLT2 inhibitors: part 3. Effects on diabetic complications in type 2 diabetic mice. Eur J Pharmacol 809 (2017), 163–171.
76. Gaspari, T, Spizzo, I, Liu, H, Hu, Y, Simpson, RW, Widdop, RE, et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis. Diab Vasc Dis Res 15 (2018), 64–73.
77. Lee, DM, Battson, ML, Jarrell, DK, Hou, S, Ecton, KE, Weir, TL, et al. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol, 17, 2018, 62.
78. Lin, B, Koibuchi, N, Hasegawa, Y, Sueta, D, Toyama, K, Uekawa, K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol, 13, 2014, 148.
79. Steven, S, Oelze, M, Hanf, A, Kroller-Schon, S, Kashani, F, Roohani, S, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol 13 (2017), 370–385.
80. Salim, HM, Fukuda, D, Yagi, S, Soeki, T, Shimabukuro, M, Sata, M, Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Front Cardiovasc Med, 3, 2016, 43.
81. El-Daly, M, Pulakazhi Venu, VK, Saifeddine, M, Mihara, K, Kang, S, Fedak, PWM, et al. Hyperglycaemic impairment of PAR2-mediated vasodilation: prevention by inhibition of aortic endothelial sodium-glucose-co-transporter-2 and minimizing oxidative stress. Vascul Pharmacol 109 (2018), 56–71.
82. Oelze, M, Kroller-Schon, S, Welschof, P, Jansen, T, Hausding, M, Mikhed, Y, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One, 9, 2014, e112394.
83. Shigiyama, F, Kumashiro, N, Miyagi, M, Ikehara, K, Kanda, E, Uchino, H, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol, 16, 2017, 84.
84. Solini, A, Giannini, L, Seghieri, M, Vitolo, E, Taddei, S, Ghiadoni, L, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol, 16, 2017, 138.
85. Sugiyama, S, Jinnouchi, H, Kurinami, N, Hieshima, K, Yoshida, A, Jinnouchi, K, et al. The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus. Intern Med 57 (2018), 2147–2156.
86. Tanaka, A, Shimabukuro, M, Okada, Y, Taguchi, I, Yamaoka-Tojo, M, Tomiyama, H, et al. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol, 16, 2017, 48.
87. Donath, MY, Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia 59 (2016), 679–682.
88. Marchetti, P, Islet inflammation in type 2 diabetes. Diabetologia 59 (2016), 668–672.
89. Eguchi, K, Nagai, R, Islet inflammation in type 2 diabetes and physiology. J Clin Invest 127 (2017), 14–23.
90. Lytrivi, M, Igoillo-Esteve, M, Cnop, M, Inflammatory stress in islet beta-cells: therapeutic implications for type 2 diabetes?. Curr Opin Pharmacol 43 (2018), 40–45.
91. Maedler, K, Sergeev, P, Ris, F, Oberholzer, J, Joller-Jemelka, HI, Spinas, GA, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110 (2002), 851–860.
92. Chen, L, Klein, T, Leung, PS, Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med 12 (2012), 995–1004.
93. Everett, BM, Donath, MY, Pradhan, AD, Thuren, T, Pais, P, Nicolau, JC, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol 71 (2018), 2392–2401.
94. Naznin, F, Sakoda, H, Okada, T, Tsubouchi, H, Waise, TM, Arakawa, K, et al. Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur J Pharmacol 794 (2017), 37–44.
95. Moller, K, Ostermann, AI, Rund, K, Thoms, S, Blume, C, Stahl, F, et al. Influence of weight reduction on blood levels of C-reactive protein, tumor necrosis factor-alpha, interleukin-6, and oxylipins in obese subjects. Prostaglandins Leukot Essent Fatty Acids 106 (2016), 39–49.
96. Berk, KA, Oudshoorn, TP, Verhoeven, AJM, Mulder, MT, Roks, AJM, Dik, WA, et al. Diet-induced weight loss and markers of endothelial dysfunction and inflammation in treated patients with type 2 diabetes. Clin Nutr ESPEN 15 (2016), 101–106.
97. Yadav, R, Hama, S, Liu, Y, Siahmansur, T, Schofield, J, Syed, AA, et al. Effect of Roux-en-Y bariatric surgery on lipoproteins, insulin resistance, and systemic and vascular inflammation in obesity and diabetes. Front Immunol, 8, 2017, 1512.
98. Cai, X, Yang, W, Gao, X, Chen, Y, Zhou, L, Zhang, S, et al. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. Obesity 26 (2018), 70–80.
99. Bolinder, J, Ljunggren, O, Kullberg, J, Johansson, L, Wilding, J, Langkilde, AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97 (2012), 1020–1031.
100. Esposito, K, Nappo, F, Marfella, R, Giugliano, G, Giugliano, F, Ciotola, M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106 (2002), 2067–2072.
101. Perkins, JM, Joy, NG, Tate, DB, Davis, SN, Acute effects of hyperinsulinemia and hyperglycemia on vascular inflammatory biomarkers and endothelial function in overweight and obese humans. Am J Physiol Endocrinol Metab 309 (2015), E168–E176.
102. Djindjic, B, Kostic, T, Radovanovic, Z, Djindjic, N, Lazovic, M, Zivic, M, et al. The contributions of fasting and postprandial blood glucose increments to oxidative stress and inflammation in dyslipidemic type 2 diabetic patients with stable ischemic heart disease. Int J Cardiol 227 (2017), 611–616.
103. Dror, E, Dalmas, E, Meier, DT, Wueest, S, Thevenet, J, Thienel, C, et al. Postprandial macrophage-derived IL-1beta stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol 18 (2017), 283–292.
104. Pedersen, DJ, Guilherme, A, Danai, LV, Heyda, L, Matevossian, A, Cohen, J, et al. A major role of insulin in promoting obesity-associated adipose tissue inflammation. Mol Metab 4 (2015), 507–518.
105. Kumar, D, Shankar, K, Patel, S, Gupta, A, Varshney, S, Gupta, S, et al. Chronic hyperinsulinemia promotes meta-inflammation and extracellular matrix deposition in adipose tissue: Implications of nitric oxide. Mol Cell Endocrinol 477 (2018), 15–28 [Epub ahead of print].
106. Ekholm, E, Hansen, L, Johnsson, E, Iqbal, N, Carlsson, B, Chen, H, et al. Combined treatment with saxagliptin plus dapagliflozin reduces insulin levels by increased insulin clearance and improves beta-cell function. Endocr Pract 23 (2017), 258–265.
107. Zhao, Y, Xu, L, Tian, D, Xia, P, Zheng, H, Wang, L, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 20 (2018), 458–462.
108. Chino, Y, Samukawa, Y, Sakai, S, Nakai, Y, Yamaguchi, J, Nakanishi, T, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35 (2014), 391–404.
109. Braga, TT, Forni, MF, Correa-Costa, M, Ramos, RN, Barbuto, JA, Branco, P, et al. Soluble uric acid activates the NLRP3 inflammasome. Sci Rep, 7, 2017, 39884.
110. Spiga, R, Marini, MA, Mancuso, E, Di Fatta, C, Fuoco, A, Perticone, F, et al. Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-kappaB signaling pathway in HepG2 cells. Arterioscler Thromb Vasc Biol 37 (2017), 1241–1249.
111. Kushiyama, A, Tanaka, K, Hara, S, Kawazu, S, Linking uric acid metabolism to diabetic complications. World J Diabetes 5 (2014), 787–795.
112. Ferrannini, E, Baldi, S, Frascerra, S, Astiarraga, B, Heise, T, Bizzotto, R, et al. Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients. Diabetes 65 (2016), 1190–1195.
113. Al Jobori, H, Daniele, G, Adams, J, Cersosimo, E, Triplitt, C, DeFronzo, RA, et al. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes Metab 19 (2017), 809–813.
114. Polidori, D, Iijima, H, Goda, M, Maruyama, N, Inagaki, N, Crawford, PA, Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium-glucose co-transporter 2 inhibitor canagliflozin. Diabetes Obes Metab 20 (2018), 1321–1326.
115. Newman, JC, Verdin, E, Ketone bodies as signaling metabolites. Trends Endocrinol Metab 25 (2014), 42–52.
116. Hughes, MM, O'Neill, LAJ, Metabolic regulation of NLRP3. Immunol Rev 281 (2018), 88–98.
117. Youm, YH, Nguyen, KY, Grant, RW, Goldberg, EL, Bodogai, M, Kim, D, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21 (2015), 263–269.
118. Yamanashi, T, Iwata, M, Kamiya, N, Tsunetomi, K, Kajitani, N, Wada, N, et al. Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses. Sci Rep, 7, 2017, 7677.
119. Rahman, M, Muhammad, S, Khan, MA, Chen, H, Ridder, DA, Muller-Fielitz, H, et al. The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat Commun, 5, 2014, 3944.
120. Shimazu, T, Hirschey, MD, Newman, J, He, W, Shirakawa, K, Le Moan, N, et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339 (2013), 211–214.
121. Prattichizzo, F, De Nigris, V, Micheloni, S, La Sala, L, Ceriello, A, Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component?. Diabetes Obes Metab, 2018, 10.1111/dom.13488 [Epub ahead of print].
122. Mancini, SJ, Boyd, D, Katwan, OJ, Strembitska, A, Almabrouk, TA, Kennedy, S, et al. Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep, 8, 2018, 5276.
123. Hawley, SA, Ford, RJ, Smith, BK, Gowans, GJ, Mancini, SJ, Pitt, RD, et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65 (2016), 2784–2794.
124. Zhou, H, Wang, S, Zhu, P, Hu, S, Chen, Y, Ren, J, Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol 15 (2018), 335–346.
125. Ott, C, Jacobs, K, Haucke, E, Navarrete Santos, A, Grune, T, Simm, A, Role of advanced glycation end products in cellular signaling. Redox Biol 2 (2014), 411–429.